IDiyas

For the Inventor, By the Inventor

Berlin, Germany

Max-delbrueck-centrum Fuer Molekulare Medizin


USPTO Granted Patents = 18


Forward Citations = 29

Loading Chart...
Loading Chart...

59 inventors (with patents filed for the assignee):

goldMedal Gerd Wallukat (5 out of 13 patents)

silverMedal Dolores Schendel (4 out of 21 patents)

bronzeMedal Susanne Wilde (4 out of 6 patents)

4.  Wolf-Hagen Schunck (3 out of 5 patents)

5.  Robert Fischer (3 out of 7 patents)

6.  Dominik N Mueller (3 out of 4 patents)

7.  Wolfgang Uckert (3 out of 12 patents)

8.  Bernhard Frankenberger (3 out of 4 patents)

9.  John Russell Falck (3 out of 34 patents)

10.  Thomas Blankenstein (2 out of 11 patents)

11.  Cosima Arnold (2 out of 3 patents)

12.  Narender Puli (2 out of 3 patents)

13.  Annekathrin Haberland (2 out of 5 patents)

14.  Ingolf Schimke (2 out of 3 patents)

15.  Anne Konkel (1 out of 3 patents)


18 patents:

1. 11365183 - Eicosanoid derivatives (2022-06-21),
2. 11130772 - CYP-eicosanoid derivatives (2021-09-28),
3. 10626159 - High affinity T cell receptor and use thereof (2020-04-21),
4. 10526577 - TGIF2-induced reprogramming of hepatic cells to pancreatic progenitor cells and medical uses thereof (2020-01-07),
5. 10287262 - Eicosanoid derivatives (2019-05-14),
6. 10266830 - Use of aptamers in therapy and/or diagnosis of autoimmune diseases (2019-04-23),
7. 10082499 - Short term isotope pulse labeling method for analysing metabolic products in biological samples (2018-09-25),
8. 9927423 - LRRC8 proteins and protein complexes and methods for identification of channel modulators (2018-03-27),
9. 9862755 - High affinity T cell receptor and use thereof (2018-01-09),
10. 9492495 - Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth (2016-11-15),
11. 9409969 - Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof (2016-08-09),
12. 9238837 - Biomarkers for determination of temporal phase of acute kidney injury (2016-01-19),
13. 9234201 - Use of aptamers in therapy and/or diagnosis of autoimmune diseases (2016-01-12),
14. 9061058 - Use of Pol III promoters for controlled expression of therapeutic proteins (2015-06-23),
15. 8974768 - Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates (2015-03-10),
The Max-Delbrück-Centrum für Molekulare Medizin (MDC) is a leading research institute in the field of molecular medicine located in Berlin, Germany. It focuses on understanding the molecular basis of diseases and developing new approaches for prevention, diagnosis, and treatment. The MDC collaborates with national and international partners in academia, industry, and clinics to bring scientific discoveries into clinical practice. With state-of-the-art facilities and renowned researchers, the MDC strives for excellence in basic and translational research to improve human health.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

18 Patents

#54 in D-1000 Berlin

#2,403 in Germany

#33,129 in the World

...
Berlin, Germany

Max-delbrueck-centrum Fuer Molekulare Medizin

Forward Citations = 29

59 inventors:

goldMedal Gerd Wallukat (5 out of 13 patents)

silverMedal Dolores Schendel (4 out of 21 patents)

bronzeMedal Susanne Wilde (4 out of 6 patents)

4.  Wolf-Hagen Schunck (3 out of 5 patents)

5.  Robert Fischer (3 out of 7 patents)

Please report any incorrect information to support@idiyas.com
Loading…